Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 416 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 416 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60. Following the transaction, the insider owned 50,437 shares of the company’s stock, valued at approximately $1,619,027.70. The trade was a 0.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.75, for a total transaction of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total value of $6,748,879.30.

Mineralys Therapeutics Price Performance

MLYS opened at $31.93 on Wednesday. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $47.65. The stock has a market capitalization of $2.53 billion, a P/E ratio of -10.82 and a beta of 0.49. The business has a 50 day simple moving average of $37.86 and a 200-day simple moving average of $31.54.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. Research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Institutional Trading of Mineralys Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Mineralys Therapeutics by 51.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after buying an additional 676 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after buying an additional 1,197 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Mineralys Therapeutics during the second quarter valued at approximately $91,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Mineralys Therapeutics by 14,091.3% during the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after buying an additional 3,241 shares during the period. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus lifted their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. HC Wainwright upped their target price on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Finally, Wells Fargo & Company raised their price target on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.43.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.